With the business potentially at an important milestone, we thought we'd take a closer look at PolyNovo Limited's (ASX:PNV) future prospects. PolyNovo Limited develops medical devices in the United States, Australia, New Zealand, the United Kingdom, Ireland, Singapore, and internationally. On 30 June 2023, the AU$911m market-cap company posted a loss of AU$4.9m for its most recent financial year. As path to profitability is the topic on PolyNovo's investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.

Check out our latest analysis for PolyNovo

Consensus from 8 of the Australian Medical Equipment analysts is that PolyNovo is on the verge of breakeven. They expect the company to post a final loss in 2023, before turning a profit of AU$152k in 2024. The company is therefore projected to breakeven around 12 months from now or less. We calculated the rate at which the company must grow to meet the consensus forecasts predicting breakeven within 12 months. It turns out an average annual growth rate of 54% is expected, which signals high confidence from analysts. Should the business grow at a slower rate, it will become profitable at a later date than expected. earnings-per-share-growth

Given this is a high-level overview, we won’t go into details of PolyNovo's upcoming projects, however, keep in mind that by and large a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.

One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 4.9% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are key fundamentals of PolyNovo which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at PolyNovo, take a look at PolyNovo's company page on Simply Wall St. We've also compiled a list of essential factors you should further examine:

Valuation: What is PolyNovo worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether PolyNovo is currently mispriced by the market. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on PolyNovo’s board and the CEO’s background. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.